What is the Impact of PrEP and ART on HIV Prevention?

April 28, 2021
John Parkinson

John Parkinson is the senior editor for ContagionLive. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at [email protected]

This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.

Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.

In this episode, our 1 Big Question is: With the greater adaption of pre-exposure prophylaxis (PrEP) therapy and the significant impact antiretroviral therapy (ART) has had, do you think medicine is doing a better job at HIV care and prevention?

We interviewed Ann Melvin, MD, MPH, director of HIV Program, Seattle Children’s Hospital; Jessica Islam, PhD, MPH, epidemiologist, Moffitt Cancer Center; Parastu Kaisie, PhD, assistant scientist, Johns Hopkins Bloomberg School of Public Health; and Patricia de los Rios, Global Medical Affairs director, ViiV Healthcare.

Check out the video to hear their insights.